Veeva Systems Inc.
Veeva Systems (VEEV) is a cloud‑software company focused on the life sciences industry, providing CRM, clinical, regulatory, quality and data platforms designed for pharmaceutical, biotech and medical‑device firms. It operates a subscription‑based model with high recurring revenue, which has supported steady margins and cash generation as the sector digitises. Key growth drivers include continued R&D outsourcing, regulatory complexity that favours specialised vendors, international expansion and cross‑selling of new modules to existing customers. Investors should note Veeva’s exposure to the healthcare sector and customer concentration in large pharma, which can amplify cyclicality. The shares currently reflect a premium for software‑like margins and growth; valuation and future revenue growth are important to watch. This is general information, not personal financial advice — returns can be volatile and past performance is not a guarantee. Consider whether the company’s sector concentration and valuation fit your risk tolerance and investment horizon.
Why It's Moving
Veeva Systems shares slide amid growth slowdown fears despite recent earnings beat.
Veeva Systems (VEEV) dropped 3% this week as technical selling pressures overshadowed its strong fiscal Q3 results, where revenue and EPS exceeded expectations. Investors are reacting to projections of decelerating revenue growth to 10.8-11.6% in the coming periods, tempering enthusiasm for the life sciences cloud leader.
- Q3 revenue hit $811M, topping estimates by 2.4%, with EPS of $2.04 beating forecasts by 4.6%, signaling robust execution in pharma software.
- Guidance raised for Q4 and FY profit, but analysts flag revenue growth slowing to 10.8% over next 12 months from recent 15-16% pace.
- Raymond James cut price target to $320 from $340 yet kept Outperform, citing impressive strategic wins with pharma clients amid CRM challenges.
Veeva Systems shares slide amid growth slowdown fears despite recent earnings beat.
Veeva Systems (VEEV) dropped 3% this week as technical selling pressures overshadowed its strong fiscal Q3 results, where revenue and EPS exceeded expectations. Investors are reacting to projections of decelerating revenue growth to 10.8-11.6% in the coming periods, tempering enthusiasm for the life sciences cloud leader.
- Q3 revenue hit $811M, topping estimates by 2.4%, with EPS of $2.04 beating forecasts by 4.6%, signaling robust execution in pharma software.
- Guidance raised for Q4 and FY profit, but analysts flag revenue growth slowing to 10.8% over next 12 months from recent 15-16% pace.
- Raymond James cut price target to $320 from $340 yet kept Outperform, citing impressive strategic wins with pharma clients amid CRM challenges.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Veeva's stock with a target price of $310.18, indicating significant growth potential.
Financial Health
Veeva Systems is performing well with strong revenue and cash flow, indicating good business health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring VEEV
Pharmaceutical Policy Shift Explained | Pricing Models
The Trump administration's recent drug pricing agreements with major pharmaceutical companies like AstraZeneca and Pfizer aim to lower U.S. drug costs by tying them to international prices. This creates a potential investment opportunity in pharmaceutical firms with strong domestic production and those in the healthcare supply chain that can adapt to the new pricing landscape.
Published: October 12, 2025
Explore BasketHealthcare's Efficiency Imperative
UnitedHealth Group's recent profit miss, driven by high medical costs, has triggered a major cost-cutting initiative across the company. This move signals a broader industry trend, creating an investment opportunity in companies that provide AI and technology solutions to help healthcare organizations improve efficiency and reduce operational expenses.
Published: July 30, 2025
Explore BasketSaaS & Cloud Computing
Invest in the digital revolution that's reshaping how businesses operate worldwide. This collection of carefully selected stocks represents companies at the forefront of software innovation, cloud technology, and digital transformation.
Published: May 23, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Recurring revenue model
Subscription contracts create predictable revenue and strong margins, though future growth depends on new customer wins and cross‑selling to existing clients.
Global pharma footprint
Veeva benefits from long relationships with major pharmaceutical companies and international expansion, but customer concentration can increase sector sensitivity.
Product innovation focus
Ongoing investment in specialised modules and data services supports cross‑sell opportunities, though competition and regulatory changes can affect adoption rates.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
Agilent Technologies Inc.
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
Align Technology Inc.
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
